2 / 7
allied
academies
Page 10
Virology Research Journal
Volume 1 Issue 4
Notes:
Vaccines World 2017
November 09-10, 2017 Vienna, Austria
21
st
World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Andreas Meinke, Virol Res J 2017, 1:4
A novel Lyme borreliosis vaccine protecting
against all major borrelia infections
L
yme borreliosis (LB) or Lyme disease is the most
common vector-borne disease in the northern
hemisphere and at present there is no vaccine available
to prevent infections. Recent analyses showed that
the number of infections in the US and Europe are
largely underreported, emphasizing the need for an
effective vaccine. An OspA (Outer surface protein A)
based vaccine (LYMErix™) was previously shown to
be efficacious against disease caused by the most
prevalent
B. burgdorferi
in the US. In Europe, the
majority of LB cases are caused by four different Borrelia
species expressing six different OspA serotypes. Since
Outer surface protein A (OspA) is one of the dominant
antigens expressed by the spirochetes when present in
the tick vector we have developed a vaccine for global
use, consisting only of the C-terminal part of OspA
which is sufficient for protection. To target the Borrelia
species expressing the six different OspA serotypes
prevalent in US and Europe, we have designed a
multivalent OspA-based vaccine (VLA15), including
three proteins, each containing the C-terminal half
of two OspA serotypes linked to form a single fusion
protein. The OspA fusion proteins were at least 85%
triacylated which ensured high immunogenicity and
were highly purified for further preclinical testing. Active
immunization with the adjuvanted Lyme borreliosis
vaccine VLA15 protected mice from a challenge with
spirochetes expressing either OspA serotype 1, 2, 4, 5
or 6, using infected ticks or
in vitro
grown bacteria as
a challenge. Further immunological analyses (ELISA,
surface binding and growth inhibition) indicated that the
vaccine can provide protection against the majority of
human pathogenic Borrelia species, including OspA
serotype 3. This rational designed VLA15 vaccine was
therefore prepared for evaluation in a first-in-man study
which currently ongoing.
Recent Publications
• Comstedt P, Schüler W, Meinke A and Lundberg L
(2017) The novel Lyme borreliosis vaccine VLA15
shows broad protection against Borrelia species
expressing six different OspA serotypes. PLOS
ONE. 1:12(9):e0184357.
• Roques P, Ljungberg K, Kümmerer BM, Gosse L,
Andreas Meinke
Valneva Austria GmbH, Austria